Editas' gene-editing data has company touting prime time based on early vision improvement signals but questions remain

CRISPR/Cas9 gene-editing biotech Editas now has its own proof-of-concept human data for vision loss therapy EDIT-101 to present today, Sept. 29, at the XIXth International Symposium on Retinal Degeneration in Nashville, Tennessee.